Session » SpA Including PsA – Treatment Poster II

Date: Sunday, November 17, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 1472

Achievement of Low Disease Activity/Remission in Guselkumab-Treated Patients with Moderately-Highly Active Psoriatic Arthritis Regardless of Baseline Characteristics: Pooled Post-Hoc Analysis of Two Phase 3/Randomized Studies

10:30AM-12:30PM: Abstract Number: 1466

Apremilast Treatment in Early Oligoarticular Psoriatic Arthritis Improves Clinical and Patient-Reported Outcomes for up to 48 Weeks – Data from a Phase 4 Trial

10:30AM-12:30PM: Abstract Number: 1478

Associations Between Clinical Characteristics and Screening MRI Findings: Exploratory Analysis of the Ongoing Phase 4, Multicenter, Randomized, Controlled STAR Study of Biologic-Naïve Patients with PsA with MRI-Confirmed Axial Involvement

10:30AM-12:30PM: Abstract Number: 1475

Baseline Characteristics and Efficacy in Patients with Radiographic AxSpA (r-axSpA) Stratified by CRP Level: An Analysis from the Ixekizumab Phase III Trial

10:30AM-12:30PM: Abstract Number: 1462

Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab versus Subcutaneous IL-17A Inhibitors

10:30AM-12:30PM: Abstract Number: 1459

Dietary Modification and Intermittent Fasting Are Common in Patients with Axial Spondylarthritis and May Lead to Reduced Inflammatory Activity

10:30AM-12:30PM: Abstract Number: 1479

Effectiveness of B/tsDMARDs Including Ixekizumab Per Line of Therapy and Concomitant CsDMARDs in Psoriatic Arthritis: Real-World Data from a Prospective Observational Study

10:30AM-12:30PM: Abstract Number: 1453

Efficacy and Safety of the Recombinant Anti-human IL-17A/F Humanized Monoclonal Antibody Injection (XKH004) in Patients with Active Ankylosing Spondylitis: Findings from a 24-Week, Phase 2 Multicenter, Randomized, Placebo-Controlled Study

10:30AM-12:30PM: Abstract Number: 1468

Efficacy of bDMARDs in Early versus Established Disease in Axial Spondyloarthritis: A Meta-Analysis of Randomized Trials

10:30AM-12:30PM: Abstract Number: 1474

Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

10:30AM-12:30PM: Abstract Number: 1464

Guselkumab and IL-17 Inhibitors Show Comparable Treatment Persistence and Effectiveness in Psoriatic Arthritis: 6-month Interim Results of the PsABIOnd Observational Cohort Study

10:30AM-12:30PM: Abstract Number: 1455

Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients with Psoriatic Arthritis

10:30AM-12:30PM: Abstract Number: 1476

Individualizing NSAIDs in Axial Spondyloarthritis Through a Series of N-of-1 Clinical Trials with Bayesian Analysis

10:30AM-12:30PM: Abstract Number: 1463

Investigation of the Cardiometabolic-related Mechanism of Action of Apremilast Through Plasma Proteomics Profiling of Patients with Psoriasis or Psoriatic Arthritis from Three Phase 3 Studies

10:30AM-12:30PM: Abstract Number: 1469

Manhattan Study: Observational, Ambispective Study to Describe Persistence and Effectiveness of a Second-line Guselkumab or TNF Inhibitors After First-line TNF Inhibitors for the Treatment of Active Psoriatic Arthritis in Spain

10:30AM-12:30PM: Abstract Number: 1473

Patient-Reported Symptoms Improved with Stringent Control of Swollen Joints in Patients with Psoriatic Arthritis: Results from Two Phase 3 Studies of Bimekizumab

10:30AM-12:30PM: Abstract Number: 1470

Patients with Psoriatic Arthritis from a Phase 4 Head-to-Head Study Stratified by Nail Involvement

10:30AM-12:30PM: Abstract Number: 1482

Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial

10:30AM-12:30PM: Abstract Number: 1456

Real-World Treat-to-Target Strategy in Psoriatic Arthritis: Baseline Characteristics from the MONITOR-PsA Cohort

10:30AM-12:30PM: Abstract Number: 1460

Safety and Effectiveness of 97 Combinations of Targeted Therapies in Immune Mediated Inflammatory Diseases : Preliminary Data from the COMBATT Registry

10:30AM-12:30PM: Abstract Number: 1481

Safety of Secukinumab in Patients with Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis and Hidradenitis Suppurativa: Updated Pooled Data from 69 Clinical Trials

10:30AM-12:30PM: Abstract Number: 1471

Sex-related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta-analysis

10:30AM-12:30PM: Abstract Number: 1480

Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies

10:30AM-12:30PM: Abstract Number: 1458

Synovial Transcriptomic Sex-Specific Differences in the Response to Biologics in Psoriatic Arthritis Patients

10:30AM-12:30PM: Abstract Number: 1465

The Use of Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease Questionnaire to Assess Patient Perceptions of Disease Burden in Patients with Early Oligoarticular Psoriatic Arthritis Treated with Apremilast in a Phase 4 Trial

10:30AM-12:30PM: Abstract Number: 1467

Time to First Clinically Meaningful Efficacy Responses in Musculoskeletal and Patient Reported Outcomes in Patients with Active Psoriatic Arthritis Treated with Risankizumab: A Post Hoc Analysis of the Phase 3 KEEPsAKE 1 and KEEPsAKE 2 Trials

10:30AM-12:30PM: Abstract Number: 1457

Treat-to-Target Approaches in Early Psoriatic Arthritis: Early Secukinumab versus Standard Care – 12- and 24-Week Results from a Multicenter, Open-Label, Randomized Controlled Trial

10:30AM-12:30PM: Abstract Number: 1454

Treatment Patterns, Clinical Characteristics, and Patient-Reported Outcomes Among Patients with Axial Spondyloarthritis Treated in Real-World Rheumatology Practices in the US

10:30AM-12:30PM: Abstract Number: 1461

Uveitis in Axial Spondyloarthritis: Study of 309 Patients in a Single University Center

10:30AM-12:30PM: Abstract Number: 1477

Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].